Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lutetium Lu 177-DOTA-EB-TATE

Radiopharmaceutical · Kills target cells, directed at somatostatin receptor 2 (SSTR2) · developed by Molecular Targeting Technologies

Phase 1 Most advanced trial (none active)
MOLN Developer
1 Registered trials

What is Lutetium Lu 177-DOTA-EB-TATE?

Lutetium Lu 177-DOTA-EB-TATE is a radioconjugate of a tyrosine-containing somatostatin analog (Tyr3-octreotate) linked to a DOTA chelator carrying the beta-emitting isotope lutetium-177, with an Evans blue moiety that binds albumin. It binds somatostatin receptor 2 on neuroendocrine tumor cells, is internalized, and delivers beta radiation to those cells. It is studied in neuroendocrine tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
177Lu-DOTA-EB-TATE
Drug type
Radiopharmaceutical
Targets
somatostatin receptor 2 (SSTR2)
Mechanism
Kills target cells, directed at somatostatin receptor 2 (SSTR2)
Pathways
albumin binding
Therapy area
Oncology
Developer
Molecular Targeting Technologies, Inc. (MOLN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05475210 Phase 1 Neuroendocrine Tumors Completed MOLN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Neuroendocrine Tumors

Other drugs acting on SSTR2

More from Molecular Targeting Technologies

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the MOLN page.

Follow MOLN, the company behind Lutetium Lu 177-DOTA-EB-TATE

See MOLN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MOLN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.